Pfizer (NYSE:PFE) Stock Price Up 1.1%

Pfizer Inc. (NYSE:PFE)’s share price rose 1.1% on Monday . The company traded as high as $26.40 and last traded at $26.29. Approximately 8,836,862 shares were traded during mid-day trading, a decline of 79% from the average daily volume of 41,983,879 shares. The stock had previously closed at $26.00.

Wall Street Analyst Weigh In

PFE has been the topic of a number of recent analyst reports. TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a report on Thursday, January 4th. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research note on Monday, April 15th. Finally, Guggenheim began coverage on shares of Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 target price on the stock. Eleven investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $36.33.

Pfizer Price Performance

The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. The firm has a market capitalization of $149.04 billion, a PE ratio of 73.11, a P/E/G ratio of 1.18 and a beta of 0.61. The company has a 50-day moving average price of $27.07 and a 200-day moving average price of $28.52.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. The company had revenue of $14.25 billion for the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm’s quarterly revenue was down 41.3% on a year-over-year basis. During the same period in the prior year, the firm earned $1.14 EPS. Sell-side analysts forecast that Pfizer Inc. will post 2.24 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Briaud Financial Planning Inc acquired a new stake in Pfizer during the 3rd quarter worth approximately $30,000. Mizuho Securities Co. Ltd. purchased a new position in Pfizer in the 3rd quarter valued at about $34,000. VisionPoint Advisory Group LLC lifted its stake in shares of Pfizer by 52,350.0% in the third quarter. VisionPoint Advisory Group LLC now owns 1,049 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 1,047 shares in the last quarter. GoalVest Advisory LLC grew its stake in Pfizer by 304.9% during the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 811 shares in the last quarter. Finally, Creekmur Asset Management LLC purchased a new stake in Pfizer during the 4th quarter worth approximately $32,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.